MASI

Masimo Celebrates Multiple Wins at the iF DESIGN AWARDS 2024

Retrieved on: 
Thursday, March 7, 2024

Masimo (NASDAQ: MASI) is proud to celebrate multiple wins across various categories at the prestigious iF DESIGN AWARDS 2024, showcasing its commitment to excellence in design and innovation throughout diverse industries.

Key Points: 
  • Masimo (NASDAQ: MASI) is proud to celebrate multiple wins across various categories at the prestigious iF DESIGN AWARDS 2024, showcasing its commitment to excellence in design and innovation throughout diverse industries.
  • The recognition from iF DESIGN AWARDS reaffirms Masimo's dedication to pushing the boundaries of design and technology to improve the lives of people around the world.
  • Joe Kiani, Founder and CEO of Masimo, said, “We are honored to be recognized by iF Design.
  • Masimo remains committed to advancing healthcare technologies and enhancing consumer experiences through cutting-edge design and innovation.

Masimo to Present in 45th Annual Raymond James Institutional Investors Conference

Retrieved on: 
Monday, March 4, 2024

Masimo (NASDAQ: MASI) today announced that its management will participate in the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5, 2024 at 3:25 p.m. Eastern Time.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that its management will participate in the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5, 2024 at 3:25 p.m. Eastern Time.
  • A live webcast of the presentation will be available on the Masimo website at www.masimo.com .
  • A replay of the webcast will be available following the live presentation.

Masimo and UCHealth Announce a Clinical Monitoring Partnership to Improve Care with Telehealth

Retrieved on: 
Tuesday, February 20, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240220607145/en/
    Joe Kiani, Founder and CEO of Masimo, said, “We are grateful for the opportunity to collaborate with world-class organizations like UCHealth.
  • “We are particularly excited by Masimo’s innovations in telehealth, virtual and remote care, and how they can help us support improved outcomes for our patients and for people everywhere.”
    Opportunities for collaboration between Masimo and UCHealth may include:
    Offering innovative virtual care and remote monitoring solutions, through the optimization of enterprise patient monitoring technologies, patient flow management, and advanced analytics.
  • Augmenting UCHealth’s expertise in evidence-based clinical workflows with Masimo virtual care solutions.
  • Collaborating on innovative direct-to-consumer (D2C) and provider-to-provider (P2P) services, to introduce virtual clinical services focusing on episodic and chronic care management.

Masimo Announces the First FDA-cleared “Over-the-Counter” Fingertip Pulse Oximeter

Retrieved on: 
Tuesday, February 13, 2024

Masimo (NASDAQ: MASI) announced today FDA clearance of MightySat® Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available Over-The-Counter (OTC) direct to consumers without a prescription.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today FDA clearance of MightySat® Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available Over-The-Counter (OTC) direct to consumers without a prescription.
  • View the full release here: https://www.businesswire.com/news/home/20240213849120/en/
    Joe Kiani, Founder and CEO of Masimo, said, “Until now, consumers and even healthcare providers had no way of knowing what pulse oximeter they could trust to use at home.
  • MightySat Medical provides a direct-to-consumer option for a medical device with hospital-grade pulse oximetry technology, Masimo SET®, whose performance has been reviewed and cleared by the FDA for medical use.
  • Now, MightySat Medical with Masimo SET® provides an FDA-cleared medical device with validated accuracy without the need for a prescription.

New Peer-Reviewed Study Finds That Masimo SET® Pulse Oximetry Measures Accurately on Both Black and White People Even During Low Perfusion

Retrieved on: 
Thursday, February 8, 2024

Barker and Wilson analyzed Masimo laboratory data obtained from self-identified Black and White volunteer subjects to evaluate differences in Masimo pulse oximetry accuracy and bias on the basis of skin tone.

Key Points: 
  • Barker and Wilson analyzed Masimo laboratory data obtained from self-identified Black and White volunteer subjects to evaluate differences in Masimo pulse oximetry accuracy and bias on the basis of skin tone.
  • To that end, they abstracted Pi values from their dataset, and divided them into “low perfusion” (Pi ≤ 1) and “normal perfusion” (Pi > 1) groups.
  • For the subset of Black subjects, there was bias and precision of -0.26% ± 1.37%, and for White subjects, -0.12% ± 1.31%.
  • In the low perfusion group, there was overall bias and precision of 0.48% ± 1.59%, with accuracy of 1.64% ARMS.

Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches

Retrieved on: 
Wednesday, January 17, 2024

Masimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, welcomes the Federal Circuit’s ruling to lift the temporary stay on the import ban of certain Apple Watch models.

Key Points: 
  • Masimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, welcomes the Federal Circuit’s ruling to lift the temporary stay on the import ban of certain Apple Watch models.
  • This decision reinstates the U.S. International Trade Commission’s import ban and cease and desist order on Apple watches that were found to infringe Masimo’s patented pulse oximetry technology.
  • The Apple Watch pulse oximeter was not cleared by the United Stated Food and Drug Administration for medical use.
  • On the other hand, the Masimo W1® health watch was recently cleared by the FDA for its indicated medical uses, including continuous pulse oximetry.

Masimo Announces New Member of the Board of Directors

Retrieved on: 
Tuesday, January 16, 2024

Masimo (NASDAQ: MASI) announced today that Bob Chapek has been appointed to Masimo’s Board of Directors.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today that Bob Chapek has been appointed to Masimo’s Board of Directors.
  • As head of Disney Consumer Products, he led a period of transformation in the worlds of play, storytelling, and learning.
  • “I am thrilled to join the Masimo Board,” said Mr. Chapek.
  • As we execute our hospital to home strategy, we expect to benefit greatly from Bob’s role on our Board.”

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System

Retrieved on: 
Monday, December 18, 2023

Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby monitoring system, for prescription use with healthy and sick babies 0-18 months of age.

Key Points: 
  • Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby monitoring system, for prescription use with healthy and sick babies 0-18 months of age.
  • Leveraging the same Masimo sensor technology that monitors more than 10 million babies in hospitals every year, Stork provides continuous, accurate monitoring of a baby’s health.
  • In addition, Stork alerts parents if their baby turns over and is sleeping face down, which can be dangerous for babies.
  • For prescription use, Masimo Stork is 510(k) cleared for the following intended use: Masimo Stork is a wearable device intended for the monitoring of multiple physiological parameters.

New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation

Retrieved on: 
Monday, December 11, 2023

ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.

Key Points: 
  • ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.
  • During anesthesia, ORi was monitored using Masimo RD rainbow SET® Pulse CO-Oximetry sensors, and blood gas analysis was performed 15 minutes after OLV was initiated.
  • Of the 11 potential predictors for PaO2
  • The researchers concluded, “ORi values during one-lung ventilation were significantly correlated with PaO2 measured simultaneously.

Masimo to Present in Piper Sandler 35th Annual Healthcare Conference

Retrieved on: 
Monday, November 27, 2023

Masimo (NASDAQ: MASI) today announced that its management will participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am ET.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that its management will participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am ET.
  • A live webcast of the presentation will be available on the Masimo website at www.masimo.com .
  • A replay of the webcast will be available following the live presentation.